GeneDx Holdings (WGS) Other Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGS) has reported Other Accumulated Expenses for 7 consecutive years, with $26.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Accumulated Expenses rose 40.58% year-over-year to $26.8 million in Q2 2026; TTM through Jun 2026 was $26.8 million, a 40.58% increase from a year earlier, with the FY2025 full-year figure at $46.9 million, up 128.6% from the prior year.
• Other Accumulated Expenses was $26.8 million for Q2 2026 at GeneDx Holdings, down from $35.9 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $81.6 million in Q2 2022 and troughed at $11.1 million in Q2 2024.
• A 5-year average of $31.6 million and a median of $24.0 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses jumped 229.59% in 2022 and plunged 75.6% in 2023, its largest moves.
• Over 5 years, Other Accumulated Expenses stood at $49.7 million in 2022, then slumped by 67.13% to $16.3 million in 2023, then gained by 25.48% to $20.5 million in 2024, then surged by 128.6% to $46.9 million in 2025, then slumped by 42.75% to $26.8 million in 2026.
• The last three Other Accumulated Expenses figures came in at $26.8 million (Q2 2026), $35.9 million (Q1 2026), and $46.9 million (Q4 2025), per Business Quant data.